Poor
Needs Major Revision
Patient Risk:
Moderate
Summary
Most brand-switching, equivalence, and operational-cause claims are not supported by the provided label excerpts; only some product-strength/packaging details appear partially aligned with HOW SUPPLIED.
Category Scores
Accurate Statements
Clonazepam (Klonopin) tablets are available in specific strengths (e.g., 0.5 mg, 1 mg, 2 mg) and the label provides product/strength information.
HOW SUPPLIED excerpt lists Klonopin tablet strengths and corresponding NDCs.
When comparing clonazepam brands, you should check the exact strength (mg).
HOW SUPPLIED lists available strengths (0.5 mg, 1 mg, 2 mg).
Unsupported Statements
Clonazepam is sold under multiple brand names depending on the country and the manufacturer.
Not supported by the provided excerpts (HOW SUPPLIED does not address multiple country/manufacturer brand naming).
Common brand names of clonazepam include Klonopin and other locally marketed versions.
Klonopin is shown in the excerpt, but 'other locally marketed versions' is not supported by the provided text.
Different clonazepam brands usually have the same active ingredient (clonazepam).
The provided excerpts do not state this generalization.
Different clonazepam brands can vary in formulation and strength, including tablets versus orally disintegrating tablets and different mg strengths.
HOW SUPPLIED excerpt lists tablet strengths but does not mention orally disintegrating tablets or that different brands vary in formulation broadly.
Different clonazepam brands can vary in inactive ingredients, which can affect tolerability for some people.
Inactive-ingredient variability and tolerability impact are not addressed in the provided excerpts.
Different clonazepam brands can vary in packaging and labeling, including dose instructions and appearance.
While HOW SUPPLIED provides product specifics (strength/imprint), the excerpt does not support broad claims about packaging/labeling variations across brands.
Switching between clonazepam brands with the same dose is intended to be clinically equivalent.
No brand-switch equivalence language is present in the provided excerpts.
Individual responses to switching clonazepam brands can differ because of formulation and patient factors.
No brand-switch-specific variability statement appears in the provided excerpts.
If you change clonazepam brands, it is common for clinicians to advise monitoring symptoms and side effects.
Information for Patients excerpt provided only states a Medication Guide must be given and general instruction to take as prescribed; it does not support a brand-switch monitoring practice claim.
It is advised not to change the clonazepam dose without medical guidance when switching brands.
The provided Information for Patients excerpt does not include dose-change guidance tied to switching brands.
Clonazepam brand changes can happen due to pharmacy stock availability.
Operational reasons for brand changes are not addressed.
Clonazepam brand changes can happen due to insurance formularies.
Insurance/coverage mechanisms are not addressed.
Clonazepam brand changes can happen due to manufacturer discontinuations or supply issues.
Supply/discontinuation causes are not addressed.
When comparing clonazepam brands, you should check the dosage form (e.g., standard tablet versus other formulations).
The excerpt shows tablet availability, but does not support a general instruction about dosage-form comparisons across brands.
When comparing clonazepam brands, you should check the labeling to confirm it is clonazepam and not another benzodiazepine.
No such patient instruction is present in the provided excerpts.
Generic clonazepam products are designed to provide the same effect at the same dose as brand-name clonazepam.
No generics equivalence statement appears in the provided excerpts.
Generic clonazepam products may look different from brand-name tablets but still contain the same active drug.
Appearance differences and active-drug equivalence between generic/brand are not supported by the provided excerpts.
Contradictions
Important Omissions
No FDA-label-aligned content was provided regarding contraindications, boxed warnings, drug interactions, adverse reactions, or administration/titration/withdrawal guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are unsupported and concern brand switching, dose equivalence, and switching-related monitoring guidance; without label support in provided excerpts, these could mislead about how switching should be handled.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Major Revision
Primary Issue
Most statements are not supported by the provided label excerpts; only strength/product availability details are partially aligned with HOW SUPPLIED.
Suggested Improvement
Limit claims to what the provided label excerpts support (e.g., specific available tablet strengths/imprint/dispensing/Medication Guide requirement), and remove or rephrase unsupported brand-switching equivalence, monitoring, dose-change, and generic/brand comparability assertions.